LCR-mediated, long-term tissue-specific gene expression within replicating episomal plasmid and cosmid vectors

Area of Science:

• Molecular Biology
• Gene Therapy
• Epigenetics

Background:

• Locus control regions (LCRs) are key regulatory elements that ensure high, tissue-specific gene expression.
• Epstein-Barr virus-based plasmids (REVs) are promising vectors for gene delivery but can be prone to gene silencing.
• Gene therapy for hemoglobinopathies requires stable and sustained transgene expression.

Purpose of the Study:

• To investigate the efficacy of the human beta-globin LCR (betaLCR) in driving gene expression from REVs.
• To assess the stability and therapeutic potential of betaLCR-containing REVs for gene therapy applications.
• To determine if LCRs can prevent silencing of transgenes within episomal vectors.

Main Methods:

• Utilized stably transfected cultured cells with an Epstein-Barr virus-based plasmid (REV) containing the human beta-globin LCR (betaLCR).
• Constructed a 38-kb betaLCR minilocus-REV cosmid vector for stable retention and expression studies.
• Monitored beta-globin transgene expression and vector stability over a 2-month period in continuous culture without drug selection.

Main Results:

• The betaLCR successfully drove high levels of tissue-specific gene expression from the REV vector in cultured cells.
• The betaLCR-containing minilocus-REV cosmid vector demonstrated efficient retention and maintained therapeutic beta-globin expression for at least 60 generations.
• Inclusion of the betaLCR prevented the silencing of the beta-globin transgene, which is a common issue with REVs.

Conclusions:

• Locus control regions (LCRs) can effectively drive and maintain therapeutic gene expression from episomal vectors like REVs.
• The human beta-globin LCR (betaLCR) prevents transgene silencing in REVs, highlighting its crucial role in vector design for gene therapy.
• These findings demonstrate the feasibility of using LCR-enhanced REVs for the gene therapy of hemoglobinopathies.